Race Oncology pens key deal to seek chemo drug Bisantrene licensing
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
Race Oncology (ASX:RAC) Limited has today entered into an agreement with transaction consultancy business, Biosynergy Partners LLC, to pursue licensing and other deals for chemotherapy drug, Bisantrene.
Bisantrene is a cancer drug that was first discovered several decades ago by US pharma giant, Lederle Pharmaceuticals, and is related to the most widely used class of cancer chemotherapy drugs called 'anthracyclines'. Bisantrene has delivered impressive trial results in the treatment of several cancers including breast cancer, ovarian cancer, lymphoma and acute myeloid leukaemia (AML).
Under the agreement, potential transactions include any sale, license, partnership, collaborative venture or other arrangement, whereby an interest in Bisantrene is transferred to a third party.
Biosynergy owner, Dr Cullity — also a non-executive director of RAC — will work with Race to prepare licensing presentations and due diligence materials for prospective partners, identify and engage with potential partners, and seek to structure, negotiate and close transactions.
“We are particularly interested in exploring licensing deals, where the partner carries the cost of the proposed AML registration trial,” said Race CEO, Peter Molloy.
“We would also like to see upfront license fees paid that would represent non-dilutive funding for Race.”
Dr Cullity said Biosynergy is looking forward to working with Race to bring the bisantrene value proposition before global oncology companies.
“Our clear objective will be to drive Race shareholder value," he added.
The company noted that there is no guarantee that the agreement will lead to an acceptable licensing or other deal.
No retainer will be paid by Race to Biosynergy — however, Biosynergy will receive transaction fees, including 6% of the total consideration up to US$25 million and 3% of the total consideration over $US25 million.
In this case, 'total consideration' refers to the total proceeds and all other payments to RAC, including sale value, upfront license fees, milestone payments, R&D funding, royalties and any other consideration received in the transaction.
The agreement provides for a minimum transaction fee equivalent to 10% of the first US$6 million in total consideration and a maximum transaction fee of US$5 million, the latter equivalent to total consideration of US$142 million.
For further agreement details, you can find the announcement here.
RAC has been on an upward trajectory since Monday, and on the back of today's news surged to intra-day highs of 133% — currently at $0.23. This resulted into a "please explain" speeding ticket from the ASX this afternoon.
More about Race Oncology
The $9.7 million capped RAC is attempting to repurpose the chemotherapy drug, Bisantrene, along with other late-stage drug assets that have been overlooked by big pharma. Bisantrene offers a treatment for relapsed and refractory AML (r/r AML) and was the subject of more than 40 phase II clinical studies before it was lost in a series of pharmaceutical mergers during the 1990s.
In the US, Race owns two granted patents on Bisantrene and has secured Orphan Drug designation and Rare Paediatric Disease designation. Its goal is to complete clinical development and gain approval by the US FDA.
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.
